Serious staphylococcal infections--cyclic lipopeptides: meeting new challenges.
Graninger
W
W
D000900:Anti-Bacterial Agents / Q000737:chemistry / Q000627:therapeutic use*; D016470:Bacteremia / Q000188:drug therapy / Q000382:microbiology; D017576:Daptomycin / Q000737:chemistry / Q000627:therapeutic use*; D024881:Drug Resistance, Bacterial; D006801:Humans; D010456:Peptides, Cyclic / Q000737:chemistry / Q000627:therapeutic use*; D018461:Soft Tissue Infections / Q000188:drug therapy / Q000382:microbiology; D013203:Staphylococcal Infections / Q000188:drug therapy* / Q000382:microbiology; D013207:Staphylococcal Skin Infections / Q000188:drug therapy / Q000382:microbiology; D013211:Staphylococcus aureus / Q000187:drug effects*
D000900:Anti-Bacterial Agents; D010456:Peptides, Cyclic; D017576:Daptomycin